Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR... CASE REPoRT Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation Luiz H. de Lima Araújo, MD, MSc,* Juliana S. da Silveira, MD,† Clarissa S. Baldotto, MD,* Mauro Zukin, MD,* and Carlos G. Ferreira, MD, PhD* and phenytoine may reduce erlotinib absorption and activa- CASE REPORT tion, respectively. Nevertheless, these drugs were initially A 67-year-old woman with no history of smoking pre- maintained, given the high risk of complications associated sented with a 1-month complaint of headache and left hemi- with the use of steroids and the possibility of seizures. The paresis. She also complained of a nonproductive cough and patient progressively recovered from her central nervous a weight loss of 15 pounds during the previous 3 months. system-related symptoms; a remarkable response in all She had a good performance status (PS 1) and no comor- metastatic lesions, including resolution of the associated bidities. Magnetic resonance imaging of the brain revealed edema, sulcal effacement, and midline deviation, was dem- multiple ring-enhancing nodular lesions at the gray-white onstrated by brain magnetic resonance imaging 6 weeks matter junction with marked surrounding edema, sugges- later (Fig. 1). A major response was also observed in the tive of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology , Volume 7 (6) – Jun 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/erlotinib-in-symptomatic-brain-metastases-from-a-lung-adenocarcinoma-1r9NQBhtFn

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
eISSN
1556-1380
DOI
10.1097/JTO.0b013e31824cc34a
pmid
22588158
Publisher site
See Article on Publisher Site

Abstract

CASE REPoRT Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation Luiz H. de Lima Araújo, MD, MSc,* Juliana S. da Silveira, MD,† Clarissa S. Baldotto, MD,* Mauro Zukin, MD,* and Carlos G. Ferreira, MD, PhD* and phenytoine may reduce erlotinib absorption and activa- CASE REPORT tion, respectively. Nevertheless, these drugs were initially A 67-year-old woman with no history of smoking pre- maintained, given the high risk of complications associated sented with a 1-month complaint of headache and left hemi- with the use of steroids and the possibility of seizures. The paresis. She also complained of a nonproductive cough and patient progressively recovered from her central nervous a weight loss of 15 pounds during the previous 3 months. system-related symptoms; a remarkable response in all She had a good performance status (PS 1) and no comor- metastatic lesions, including resolution of the associated bidities. Magnetic resonance imaging of the brain revealed edema, sulcal effacement, and midline deviation, was dem- multiple ring-enhancing nodular lesions at the gray-white onstrated by brain magnetic resonance imaging 6 weeks matter junction with marked surrounding edema, sugges- later (Fig. 1). A major response was also observed in the tive of

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2012

References